Access Bio (A950130) Stock Overview
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A950130 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Access Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,360.00 |
| 52 Week High | ₩7,360.00 |
| 52 Week Low | ₩3,280.00 |
| Beta | 0.049 |
| 1 Month Change | -18.64% |
| 3 Month Change | n/a |
| 1 Year Change | -41.16% |
| 3 Year Change | -73.44% |
| 5 Year Change | -82.99% |
| Change since IPO | -67.54% |
Recent News & Updates
Access Bio, Inc.'s (KOSDAQ:950130) Popularity With Investors Under Threat As Stock Sinks 26%
Nov 12
What Access Bio, Inc.'s (KOSDAQ:950130) 28% Share Price Gain Is Not Telling You
May 22Recent updates
Access Bio, Inc.'s (KOSDAQ:950130) Popularity With Investors Under Threat As Stock Sinks 26%
Nov 12What Access Bio, Inc.'s (KOSDAQ:950130) 28% Share Price Gain Is Not Telling You
May 22Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 26% But Growth Is Lacking
Jan 06Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares
Nov 13Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking
Aug 07Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem
Mar 26Is Access Bio (KOSDAQ:950130) A Risky Investment?
Mar 25If You Had Bought Access Bio (KOSDAQ:950130) Shares A Year Ago You'd Have Earned 740% Returns
Feb 18Shareholder Returns
| A950130 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -5.1% | 1.3% | 0.9% |
| 1Y | -41.2% | -7.3% | 54.7% |
Return vs Industry: A950130 underperformed the KR Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: A950130 underperformed the KR Market which returned 54.7% over the past year.
Price Volatility
| A950130 volatility | |
|---|---|
| A950130 Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.0% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A950130's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A950130's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Young-Ho Choi | accessbio.net |
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names.
Access Bio, Inc. Fundamentals Summary
| A950130 fundamental statistics | |
|---|---|
| Market cap | ₩118.18b |
| Earnings (TTM) | -₩21.64b |
| Revenue (TTM) | ₩74.42b |
Is A950130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950130 income statement (TTM) | |
|---|---|
| Revenue | ₩74.42b |
| Cost of Revenue | ₩58.43b |
| Gross Profit | ₩15.99b |
| Other Expenses | ₩37.63b |
| Earnings | -₩21.64b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -615.23 |
| Gross Margin | 21.48% |
| Net Profit Margin | -29.08% |
| Debt/Equity Ratio | 2.4% |
How did A950130 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 21:52 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Access Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |
| Gwang Sik Park | Kyobo Securities Co., Ltd |
| Kyung-Churl Noh | SK Securities Co., Ltd. |